Altered plasma protein profiles in genetic FTD - a GENFI study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ullgren Abbe, Öijerstedt Linn, Olofsson Jennie, Bergström Sofia, Remnestål Julia, van Swieten John C, Jiskoot Lize C, Seelaar Harro, Borroni Barbara, Sanchez-Valle Raquel, Moreno Fermin, Laforce Robert, Synofzik Matthis, Galimberti Daniela, Rowe James B, Masellis Mario, Tartaglia Maria Carmela, Finger Elizabeth, Vandenberghe Rik, de Mendonça Alexandre, Tirabosch Pietro, Santana Isabel, Ducharme Simon, Butler Chris R, Gerhard Alexander, Otto Markus, Bouzigues Arabella, Russell Lucy, Swift Imogen J, Sogorb-Esteve Aitana, Heller Carolin, Rohrer Jonathan D, Månberg Anna, Nilsson Peter, Graff Caroline, Genetic Frontotemporal Dementia Initiative (GENFI)
Аннотация
METHODS: Blood samples from 693 participants in the GENetic Frontotemporal Dementia Initiative study were analysed using a multiplexed antibody array targeting 158 proteins.
RESULTS: We found 13 elevated proteins in symptomatic mutation carriers, when comparing plasma levels from people diagnosed with genetic FTD to healthy non-mutation controls and 10 proteins that were elevated compared to presymptomatic mutation carriers.
CONCLUSION: We identified plasma proteins with altered levels in symptomatic mutation carriers compared to non-carrier controls as well as to presymptomatic mutation carriers. Further investigations are needed to elucidate their potential as fluid biomarkers of the disease process.